NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $500 million of 5.150% Notes due 2029 (the "2029 Notes"); $500 million of 5.400% Notes due 2034 (the "2034 Notes"); and $500 million of 5.900% Notes due 2054 (the "2054 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The offering is expected to close on June 10, 2024, subject to the satisfaction of customary closing conditions. Royalty Pharma intends to use the net proceeds from the Notes for general corporate purposes. BofA Securities, Citigroup, J.P. Morgan, Morgan Stanley and TD Securities are acting as joint lead book-running managers and as representatives of the underwriters for the offering. DNB Markets, SMBC Nikko, SOCIETE GENERALE, US Bancorp, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, Drexel Hamilton, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Bank and Tigress Financial Partners are acting as co-managers for the offering. The Notes are being offered pursuant to an effective shelf registration statement that the Company filed with the Securities and Exchange Commission (the "SEC"). The offering is being made only by means of a preliminary prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available free of charge on the SEC's website at http://www.sec.gov. The final prospectus supplement and accompanying ...